The treatment of @entity706 still needs major improvements in order to put the @entity1 in remission and to retain graft function. Chemotherapy is far too toxic in these @entity1 . A more specific treatment such as anti-B-cell monoclonal antibody is very promising. The cytotoxic effect of antibody relies mainly on complement-induced and antibody-dependent cellular @entity137 ; apoptosis may also induce @entity5 cell death. B-cell antigens expressed on the cell surface are the targets of antibody attack; some specificities may be chosen because of their level of expression or because of signaling induced within the cell. Anti-B-cell antibodies can be produced by genetic engineering in order to be humanized or to carry bispecific Fabs. The efficacy and safety of anti-B-cell monoclonal antibodies (mAbs) in transplant @entity1 have been proven with different antibodies such as anti- @entity10911 / @entity11707 mAb, anti- @entity3053 mAb and anti- @entity2225 mAb. In a retrospective analysis of different centers in France, rituximab (anti- @entity2225 mAb, Roche Products) achieved an overall 69% remission rate in 34 organ and bone-marrow transplant @entity1 . But the conditions of use of antibody must be better defined, particularly with regard to the immunosuppressive therapy, the type of @entity5 and the dose of antibody. We must also improve our understanding of the in vivo mechanisms of action of antibody to develop more efficient antibody constructs.

Treatment of XXXX with anti-B-cell monoclonal antibodies.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity10911 :: ('1380', 'Gene') :: ['CD21'] @entity137 :: ('MESH:D064420', 'Disease') :: ['cytotoxicity'] @entity706 :: ('MESH:D008223', 'Disease') :: ['post-transplant lymphomas'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity2225 :: ('54474', 'Gene') :: ['CD20'] @entity11707 :: ('100133941', 'Gene') :: ['CD24'] @entity3053 :: ('952', 'Gene') :: ['CD38']
@entity706 :: (MESH:D008223,Disease) :: ['post-transplant lymphomas']
